CIO - Centro de Inmuno-Oncología de Occidente

CIO - Centro de Inmuno-Oncología de Occidente
Calle Santa Fe 3078, Colonia Providencia 5a sección, C.P. 44630 Guadalajara, Jalisco
Select an option

Open studies

Breast Cancer
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) - MK 2870-010 - Merck Sharp & Dohme LLCSee more
Skin cancer
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma - ABP 206 - AmgenSee more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy